• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, August 9, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Protective T cells remain 20 months after COVID-19

Bioengineer by Bioengineer
July 21, 2022
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patients infected with SARS-CoV-2 develop protective immune responses, mediated by virus-specific T cells and antibodies, shortly after the infection. There is concern, however, that immunity does not persist over time, which may translate into severe COVID-19 upon re-infection. 

Th1 cells

Credit: Martner et al/PNAS

Patients infected with SARS-CoV-2 develop protective immune responses, mediated by virus-specific T cells and antibodies, shortly after the infection. There is concern, however, that immunity does not persist over time, which may translate into severe COVID-19 upon re-infection. 

In the July, 12 issue of Proceedings of the National Academy of Sciences (PNAS), Anna Martner and co-authors at University of Gothenburg report two main findings. First, several variants of virus-specific T cells became detectable in blood shortly after COVID-19, but strikingly disappeared after 10-12 weeks.

However, a group of highly specialized T cells, designed to facilitate elimination of infected cells, remained active in the blood of all previously SARS-CoV-2-infected patients. These T cells did not disappear or wane even at long follow-up.

The findings may explain the reduced risk of severe disease and mortality among patients who have become re-infected with SARS-CoV-2.

Scientists at the University of Gothenburg and Sahlgrenska University Hospital collected 81 blood samples from hospital staff members who had contracted mild COVID-19 in the first year of the pandemic and uninfected controls. The researchers studied T cell reactivity to an inner part of SARS-CoV-2 (the virus nucleocapsid) thus capturing T cell responses that only occur after a natural infection.

The blood samples were exposed to more than 100 peptides from the nucleocapsid portion of SARS-CoV-2 virus. The researchers then analyzed which T cell mediators (cytokines) were produced by blood cells to determine the longevity of T cell reactivity after the infection.

It was observed that a subgroup of specialized T cells (Th1 cells) that promote destruction of virus-infected cells were active for at least 20 months after natural COVID-19. The infected patients also harbored several other types of T cells that reacted with SARS-CoV-2. These latter T cells disappeared from blood approximately 2 months after recovery from infection.

– While certain subsets of T cells disappear shortly after infection, highly specialized T cells (T helper 1 cells) remain stably present in blood to suggest that a vital aspect of protective immunity is functional years after COVID-19, says Anna Martner, Associate Professor of immunology at the Sahlgrenska Academy. These results may explain why re-infection with SARS-CoV-2 only rarely translates into severe COVID-19.



Journal

Proceedings of the National Academy of Sciences

DOI

10.1073/pnas.2203659119

Method of Research

Case study

Subject of Research

Human tissue samples

Article Title

Transient and durable T cell reactivity after COVID-19

Article Publication Date

12-Jul-2022

Share12Tweet7Share2ShareShareShare1

Related Posts

Renelle Myers, BC Cancer, in Vancouver, B.C.

Vancouver researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

August 9, 2022
Monocrystal

Scientists have created optical fibers with unusual properties

August 8, 2022

Elucidating the molecular targets of “eicosapentaenoic acid”: A natural remedy for chronic pain

August 8, 2022

Down on Vitamin D? It could be the cause of chronic inflammation

August 7, 2022

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    56 shares
    Share 22 Tweet 14
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    66 shares
    Share 26 Tweet 17
  • Ill-fated ‘Into the Wild’ adventurer was victim of unfortunate timing, Oregon State study suggests

    39 shares
    Share 16 Tweet 10
  • Skin: An additional tool for the versatile elephant trunk

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

WeaponryVehiclesWeather/StormsUrogenital SystemZoology/Veterinary ScienceVirusVirologyUrbanizationUniversity of WashingtonVaccineVaccinesViolence/Criminals

Recent Posts

  • Sexual dysfunction high among women with lung cancer
  • Vancouver researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked
  • Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
  • Informed consent forms for lung cancer clinical trials may be a barrier to informed trial participation
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In